```html

Jasper's Disease (Progressive Systemic Sclerosis) – A Patient‑Friendly Guide

Overview

Jasper’s disease, more formally known as **progressive systemic sclerosis (SSc‑P)**, is a rare, chronic autoimmune disorder that causes hardening (sclerosis) and fibrosis of the skin and internal organs. The condition is characterized by an overproduction of collagen, which leads to thickened skin, vascular abnormalities, and progressive damage to the lungs, heart, kidneys, gastrointestinal (GI) tract, and musculoskeletal system.

• Who it affects: Primarily adults between 30–60 years of age; women are affected about 4–5 times more often than men.
• Prevalence: Approximately 240–300 cases per million people in the United States and Europe, making it one of the less common connective‑tissue diseases, but the most severe form of systemic sclerosis.<sup>1</sup>
• Geography: Higher incidence in North America and northern Europe; lower rates reported in Asia and Africa, possibly reflecting genetic and environmental differences.

Because the disease progresses over months to years, early recognition and multidisciplinary care are essential to slow organ damage and improve quality of life.

Symptoms

Symptoms can vary widely, and they often appear in a “wave” pattern—some may improve while others worsen. Below is a comprehensive list with brief descriptions:

Skin

• Skin thickening: Tight, shiny skin that may start on the fingers (sclerodactyly) and spread up the arms, torso, and face.
• Raynaud’s phenomenon: Episodes of finger/toe blanching, followed by cyanosis and reddening when exposed to cold or stress.
• Digital ulcers: Painful sores on fingertips or toes caused by poor blood flow.
• Telangiectasias: Small, visible blood vessels on the face, lips, or hands.
• Calcinosis: Calcium deposits under the skin that can become painful or infected.

Vascular & Circulatory

• High blood pressure in the lungs (pulmonary arterial hypertension, PAH).
• Peripheral edema (swelling of hands/feet).
• Cardiac arrhythmias or conduction defects.

Respiratory

• Shortness of breath, especially on exertion.
• Dry, persistent cough.
• Interstitial lung disease (ILD) – scarring of lung tissue leading to reduced oxygen exchange.

Gastrointestinal

• Difficulty swallowing (dysphagia) due to esophageal fibrosis.
• Heartburn, acid reflux, or gastroesophageal reflux disease (GERD).
• Abdominal bloating, constipation, or diarrhoea caused by slowed gut motility.
• Malabsorption and weight loss.

Musculoskeletal

• Joint pain and stiffness, especially in the hands.
• Muscle weakness (myopathy).
• Limited range of motion from skin tightening.

Renal

• Rapidly progressive renal failure (scleroderma renal crisis).
• Hypertension and proteinuria.

General/Other

• Fatigue and low energy.
• Fever or unexplained weight loss (often a sign of active inflammation).
• Hair loss (alopecia) on the scalp or eyebrows.

Causes and Risk Factors

The exact trigger for Jasper’s disease remains unknown, but research points to a combination of genetic susceptibility, immune dysregulation, and environmental exposures.

Genetic Factors

• Family clustering is rare, yet certain HLA genes (e.g., HLA‑DRB1*11) are associated with increased risk.<sup>2</sup>
• Polymorphisms in genes related to collagen production and vascular tone (e.g., TNFAIP3) have been identified.

Immune System Abnormalities

• Autoantibodies such as anti‑topoisomerase I (Scl‑70) and anti‑centromere are hallmarks; they are not causative but reflect immune activation.
• Elevated cytokines (IL‑6, TGF‑β) drive fibroblast activation and collagen deposition.

Environmental Triggers

• Silica dust exposure: Occupational exposure (mining, sandblasting) is linked to higher incidence.<sup>3</sup>
• Organic solvents: Chronic exposure to trichloroethylene or benzene may increase risk.
• Smoking: Raises the likelihood of lung involvement (ILD, PAH).

Demographic Risk Factors

• Female sex (especially ages 30‑55).
• Northern European ancestry.
• History of other autoimmune diseases (e.g., rheumatoid arthritis, lupus).

Diagnosis

Diagnosing progressive systemic sclerosis requires a combination of clinical assessment, laboratory testing, and imaging. Early referral to a rheumatologist is crucial.

Clinical Evaluation

• Detailed history of skin changes, Raynaud’s episodes, and organ‑specific symptoms.
• Physical exam focusing on skin thickness (modified Rodnan skin score), telangiectasias, joint range of motion, and vascular signs.

Laboratory Tests

• Autoantibody panel: Anti‑topoisomerase I (Scl‑70), anti‑centromere, anti‑RNA polymerase III. Presence helps subtype disease and predicts organ involvement.
• Complete blood count, renal function, liver enzymes, ESR/CRP (inflammation markers).
• Urinalysis for proteinuria (early renal involvement).

Imaging & Functional Tests

• High‑resolution CT (HRCT) of the chest: Detects interstitial lung disease with greater sensitivity than plain X‑ray.
• Echo‑cardiography: Screens for pulmonary hypertension, pericardial effusion, and left‑ventricular dysfunction.
• Right‑heart catheterization: Gold standard to confirm PAH when echo suggests elevated pressures.
• **Pulmonary function tests (PFTs):** Measure forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO); trends indicate lung disease progression.
• **Gastrointestinal studies:** Barium swallow, esophageal manometry, or gastric emptying studies help assess dysmotility.

Diagnostic Criteria

The 2013 ACR/EULAR classification criteria for systemic sclerosis assign points for skin thickening, specific autoantibodies, and organ involvement; a total score ≥ 9 classifies a patient as having systemic sclerosis.<sup>4</sup>

Treatment Options

There is currently no cure for Jasper’s disease; therapy aims to control immune activity, limit fibrosis, and manage organ complications. Treatment is highly individualized and typically involves a multidisciplinary team (rheumatology, pulmonology, cardiology, dermatology, gastroenterology, physical therapy).

Immunomodulatory Medications

• Mycophenolate mofetil (MMF): First‑line for ILD; reduces progression of lung fibrosis (dose 1,500–3,000 mg/day).<sup>5</sup>
• Cyclophosphamide: Oral or IV pulses for severe, rapidly progressive ILD or severe skin disease; limited to 6–12 months due to toxicity.
• Rituximab (anti‑CD20): Off‑label use for refractory skin and lung disease; emerging evidence shows benefit in PAH.
• Methotrexate: Helpful for early skin thickening and arthritis; often combined with folic acid.
• Low‑dose glucocorticoids: Use cautiously (≤10 mg prednisone) because higher doses increase risk of scleroderma renal crisis.

Targeted Anti‑Fibrotic Agents

• Nintedanib: Tyrosine‑kinase inhibitor approved by the FDA (2020) for slowing decline in FVC in SSc‑ILD.<sup>6</sup>
• Pirfenidone: Investigational for SSc‑ILD; approved for idiopathic pulmonary fibrosis.

Pulmonary Arterial Hypertension Therapies

• Endothelin‑receptor antagonists (bosentan, ambrisentan).
• Phosphodiesterase‑5 inhibitors (sildenafil, tadalafil).
• Prostacyclin analogues (epoprostenol, treprostinil) for advanced disease.

Renal Protection

• Prompt treatment of scleroderma renal crisis with ACE inhibitors (e.g., captopril) – dramatically improves survival.
• Strict blood‑pressure monitoring; avoid high‑dose steroids.

Symptomatic & Supportive Care

• Raynaud’s management: Calcium channel blockers (nifedipine), topical nitrates, avoidance of cold.
• Gastro‑esophageal reflux: Proton‑pump inhibitors (omeprazole), prokinetic agents (metoclopramide), head‑of‑bed elevation.
• Skin care: Moisturizers, gentle soaps, silicone gel sheeting for ulcer prevention.
• Physical & occupational therapy: Daily stretching, splinting, and hand‑exercises to preserve range of motion.
• Vaccinations: Annual influenza, pneumococcal, and COVID‑19 vaccines to reduce infection risk.

Lifestyle Modifications

• Quit smoking and avoid secondhand smoke.
• Maintain a balanced, high‑protein diet; consider medium‑chain triglyceride supplements if malabsorption is present.
• Stay physically active within tolerance – low‑impact aerobic exercise improves cardiopulmonary reserve.
• Stress‑reduction techniques (mindfulness, yoga) may lessen Raynaud’s episodes.

Living with Jasper's disease (Progressive systemic sclerosis)

Managing a chronic, multisystem disease requires practical daily habits and a solid support network.

Practical Daily Tips

• Skin routine: Apply thick moisturizers (petrolatum‑based) after bathing; protect hands with cotton gloves in cold weather.
• Hand care: Use silicone finger sleeves at night to prevent contractures; keep nails trimmed to reduce ulcer risk.
• Heat management: Warm water bottles or hand warmers can mitigate Raynaud’s; avoid direct heat that may cause burns.
• Medication adherence: Use a weekly pill organizer and set alarms; keep a medication log.
• Monitoring: Track blood pressure (especially at home) and note any new breathlessness or swelling.
• Nutrition: Small, frequent meals; low‑acid diet if GERD; consider vitamin D supplementation (often low due to limited sun exposure).
• Exercise: Gentle yoga, swimming, or stationary cycling 3‑4 times weekly; stretch fingers for 10 minutes each session.
• Psychosocial health: Join support groups (e.g., Scleroderma Foundation), seek counseling if anxiety/depression arise.

Co‑ordination of Care

Establish a primary “scleroderma coordinator” (often a rheumatology nurse) who tracks appointments, labs, and imaging. Use an electronic health record portal to share updates with all specialists.

Prevention

Because the exact cause is not modifiable, prevention focuses on reducing known risk enhancers and early detection.

• Avoid occupational silica or solvent exposure; use protective equipment when exposure is unavoidable.
• Stop smoking and limit alcohol consumption.
• Promptly treat severe Raynaud’s attacks to prevent digital ulcers.
• Regular health‑check screenings for at‑risk relatives (especially if a first‑degree relative has an autoimmune disease).

Complications

If untreated or inadequately controlled, Jasper’s disease can lead to life‑threatening complications:

• Interstitial lung disease (ILD): Progressive respiratory failure, leading cause of mortality.
• Pulmonary arterial hypertension (PAH): Right‑heart failure.
• Scleroderma renal crisis: Acute kidney injury with malignant hypertension; mortality >50 % without ACE‑inhibitor therapy.
• Digital gangrene: Tissue loss requiring amputation.
• Malignancy: Slightly increased risk of lung, breast, and gastric cancers.
• Gastrointestinal bleeding or perforation: From severe reflux or intestinal dysmotility.
• Heart involvement: Myocardial fibrosis, pericardial effusion, arrhythmias.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Arthritis and Autoimmune Diseases. Accessed July 2026.
2. Johnston, L. et al. Genetic susceptibility in systemic sclerosis. J Autoimmun. 2022;124:102715.
3. National Institute for Occupational Safety and Health. Silica dust exposure. NIOSH. 2021.
4. Van den Hoogen, F. et al. 2013 ACR/EULAR classification criteria for systemic sclerosis. Arthritis Rheumatol. 2013;65:2737‑2747.
5. Cleveland Clinic. Systemic sclerosis (scleroderma). 2024.
6. Distler, O. et al. Nintedanib for systemic sclerosis‑associated interstitial lung disease. N Engl J Med. 2023;388:56‑66.

```